Haleos Labs (HALEOSLABS) Fundamentals 2026 — P/E 26.6x, Revenue Analysis | SniperIQ
Haleos Labs (HALEOSLABS) is a India-listed Healthcare company in Biotechnology with a market capitalization of ₹461 Crore, trading at ₹1523.70 on the NSE. This SniperIQ fundamentals page covers Haleos Labs's valuation (P/E 26.6x, P/B 2.2x), profitability (net margin 5.2%), revenue (₹334 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Haleos Labs's market cap?
Haleos Labs (HALEOSLABS) has a market capitalization of approximately ₹461 Crore, trading at ₹1523.70 on the NSE. Market cap moves with the live share price.
What is Haleos Labs's P/E ratio?
Haleos Labs's trailing twelve-month P/E ratio is 26.6x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Haleos Labs?
Haleos Labs runs a net profit margin of 5.2%, a gross margin of 25.8%, and an operating margin of 8.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Haleos Labs generate?
Haleos Labs reported revenue of ₹334 Crore for fiscal year 2025, with net income of ₹17 Crore and earnings per share (EPS) of 57.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Haleos Labs pay a dividend?
Haleos Labs offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Haleos Labs financially healthy?
Haleos Labs carries a debt-to-equity ratio of 0.52x and a current ratio of 1.04x, with a market beta of 0.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Haleos Labs a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Haleos Labs (HALEOSLABS) the key facts are: market cap ₹461 Crore, P/E 26.6x, revenue ₹334 Crore, 52-week range 1067-1774. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Haleos Labs's full fundamentals live
Get Haleos Labs's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.